{"product_id":"lnth-bcg-matrix","title":"(LNTH) Lantheus Holdings, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Lantheus Holdings, Inc. BCG Matrix helps you see how the company’s products or business units may rank across Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the analysis, so you can review the actual report format and content before buying. Purchase the full version to get the complete ready-to-use BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYLARIFY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYLARIFY is Lantheus Holdings, Inc.'s U.S. F-18 PSMA PET agent for recurrent or metastatic prostate cancer, and it remains the company's biggest growth driver. High physician adoption and repeat-scan demand support Star status in a fast-growing oncology imaging market. Its scale and category leadership make it a core cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEFINITY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEFINITY is Lantheus Holdings, Inc.’s ultrasound contrast agent for echocardiography, with broad use across hospitals and imaging centers. Its large installed base and steady cardiac imaging demand make it a Stars asset in the BCG Matrix. Continued utilization in echo supports recurring revenue and keeps DEFINITY a core growth driver for Lantheus Holdings, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePSMA PET franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePSMA PET is a Star for Lantheus Holdings, Inc. because demand keeps rising as prostate cancer imaging moves earlier in diagnosis and treatment planning. In 2025, U.S. prostate cancer cases are projected at about 313,780, and PYLARIFY remains the category leader with FY2024 sales above $1 billion, giving Lantheus strong share in a fast-growing market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePYLARIFY US commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn FY2025, PYLARIFY stayed Lantheus Holdings, Inc.'s Star, with U.S. use expanding across oncology sites, hospitals, and outpatient centers as physicians became more familiar with PSMA PET and payer coverage broadened. The brand's scale matters because each added scan helps defend share and supports durable cash generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroad U.S. site expansion.\u003c\/li\u003e\n\u003cli\u003eMore physician familiarity.\u003c\/li\u003e\n\u003cli\u003eWider payer coverage.\u003c\/li\u003e\n\u003cli\u003eShare retention drives cash flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePYLARIFY international partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePYLARIFY’s non-U.S. model is partner-led, so Lantheus can scale without building a full local sales force. That matters because PSMA PET adoption outside the U.S. is still early, but the addressable market is expanding as more systems and reimbursement paths open. In 2025, this kind of asset-light expansion helps keep margins cleaner while extending franchise peak value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner-based distribution lowers fixed cost risk\u003c\/li\u003e\n\u003cli\u003eEarly PSMA PET adoption supports high growth\u003c\/li\u003e\n\u003cli\u003eInternational reach can lengthen peak sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYLARIFY and DEFINITY Power Lantheus Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars at Lantheus Holdings, Inc. are led by PYLARIFY and DEFINITY, both with strong share in growing imaging markets. PYLARIFY crossed $1 billion in FY2024 sales and serves a 2025 U.S. prostate cancer market of about 313,780 cases, while DEFINITY’s broad hospital use supports steady recurring demand. Together they anchor growth and cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePYLARIFY\u003c\/td\u003e\n\u003ctd\u003e$1B+ FY2024 sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEFINITY\u003c\/td\u003e\n\u003ctd\u003eBroad echo use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLantheus BCG Matrix maps its portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Lantheus Holdings, Inc. that quickly clarifies growth, cash cows, and weak spots.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLantheus Holdings, Inc. reference sources give a traceable proof point for every key claim, boosting credibility and speeding smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechneLite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTechneLite is a Tc-99m generator used in nuclear medicine, and its mature install base supports steady repeat demand. Tc-99m powers about 80% of nuclear medicine imaging, so this product fits a Cash Cow profile: low-growth, high-visibility, recurring sales. Its long clinical history and wide hospital use make it a stable cash source for Lantheus Holdings, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiolite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCardiolite, Lantheus Holdings, Inc.’s Tc-99m myocardial perfusion imaging agent, is a classic Cash Cow: a mature product in a slow-growth market. Nuclear cardiology still relies on its installed base, so demand is steady even with limited upside. It has been on the market since 1990, and 99mTc remains the core isotope in this imaging class.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXenon-133\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXenon-133 is a legacy pulmonary function imaging product in Lantheus Holdings, Inc.’s portfolio, serving a narrow but durable clinical niche. Its low-growth profile and steady hospital use support cash generation more than expansion. In BCG terms, it fits a Cash Cow because mature demand and limited reinvestment needs help fund higher-growth assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRELISTOR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRELISTOR is Lantheus Holdings, Inc.'s branded methylnaltrexone for opioid-induced constipation, a mature niche with limited growth but steady demand. In Lantheus Holdings, Inc.'s FY2025 reporting, it fits the Cash Cow bucket because the brand is established, needs modest incremental promotion, and can keep converting prescription volume into cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished branded therapy\u003c\/li\u003e\n\u003cli\u003eMature, low-growth market\u003c\/li\u003e\n\u003cli\u003eCash flow with light promotion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDEFINITY mature base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDEFINITY remains Lantheus Holdings, Inc.’s cash cow: it holds a leading share in echocardiography contrast and serves a broad, steady hospital and outpatient base. Its mature installed demand profile makes revenue less volatile, and that scale helps Lantheus generate dependable operating cash for R\u0026amp;D and new launches.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeading echocardiography contrast franchise\u003c\/li\u003e\n\u003cli\u003eBroad clinical use, steady demand\u003c\/li\u003e\n\u003cli\u003eMature scale supports operating cash\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantheus Cash Cows: Recurring Demand, Steady FY2025 Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLantheus Holdings, Inc.'s Cash Cows are mature brands with repeat demand and low reinvestment needs. TechneLite and Cardiolite benefit from Tc-99m, which powers about 80% of nuclear medicine imaging, while DEFINITY and RELISTOR add steady FY2025 cash flow from established use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eCash Cow cue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechneLite\u003c\/td\u003e\n\u003ctd\u003eRecurring generator demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEFINITY\u003c\/td\u003e\n\u003ctd\u003eLeading echo contrast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eLantheus Holdings, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the actual Lantheus Holdings, Inc. BCG Matrix report you'll receive after purchase. The file shown here is the same fully formatted document, with no demo content or hidden sections. Once purchased, the complete version is instantly available for download and ready to use for analysis, printing, or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurolite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurolite is an older technetium-99m brain SPECT agent, and Lantheus Holdings, Inc. does not break out meaningful 2025\/2026 revenue for it, which points to a very small role in the portfolio. Demand is capped by newer PET and MRI options plus lower clinical use. With low growth and shrinking relevance, it fits Dog territory.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThallium-201\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThallium-201 is a legacy cardiac imaging isotope for Lantheus Holdings, Inc. and fits the Dogs quadrant: mature, low growth, and facing steady volume decline as technetium-based and PET imaging gain share. The product has limited strategic upside, and modern nuclear medicine uses it far less than in prior decades. Its role is mainly cash harvest, not growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGallium-67\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGallium-67 is an older imaging tracer for infection and tumor scans, but newer PET options have taken most of its use. Its clinical demand is now niche and shrinking, with low share and weak growth, which fits Lantheus Holdings, Inc.'s Dog bucket in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCobalt-57\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCobalt-57 is a small legacy radiochemical within Lantheus Holdings, Inc. and fits the Dogs bucket: limited commercial scale, low growth, and weak strategic pull. Lantheus reported FY2025 revenue of about $1.5 billion, but it does not break out Cobalt-57 sales, which itself signals a minor line. In BCG terms, it is more likely a cash trap than a growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy radiochemical\u003c\/li\u003e\n\u003cli\u003eMinimal disclosed scale\u003c\/li\u003e\n\u003cli\u003eLow-growth profile\u003c\/li\u003e\n\u003cli\u003eLikely cash trap\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAZEDRA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAZEDRA remains a niche therapeutic for rare pheochromocytoma\/paraganglioma use, so its commercial reach is still limited inside Lantheus Holdings, Inc. It has not scaled into a broad revenue engine, which fits a BCG Dog: low market penetration, modest growth, and weak contribution versus the Company Name’s larger growth platforms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialty use, narrow patient pool\u003c\/li\u003e\n\u003cli\u003eLimited revenue traction\u003c\/li\u003e\n\u003cli\u003eLow share in its market\u003c\/li\u003e\n\u003cli\u003eBCG Dog classification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantheus' Legacy Lines: Small, Shrinking, and Strategically Weak\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurolite, Thallium-201, Gallium-67, Cobalt-57, and AZEDRA are legacy or niche products with no meaningful FY2025\/FY2026 revenue disclosure, weak growth, and shrinking clinical use at Lantheus Holdings, Inc.\u003c\/p\u003e\n\u003cp\u003eWith Company Name FY2025 revenue near $1.5 billion, these lines look like Dog assets: low share, low growth, and limited strategic upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eBCG\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeurolite\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eVery small\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThallium-201\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eDeclining use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGallium-67\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eNiche demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCobalt-57\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eMinimal scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAZEDRA\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003ctd\u003eNarrow market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFLYRCADO, flurpiridaz F 18\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFLYRCADO, flurpiridaz F 18, fits the Question Mark bucket: it targets cardiac PET perfusion, a niche with clear clinical demand but still low share because adoption is early. Lantheus is still funding launch work to build site access, train users, and show scale, so near-term profit can stay thin. If uptake matches PET growth, it could become a meaningful growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePYLARIFY AI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePYLARIFY AI sits in the Question Mark bucket for Lantheus Holdings, Inc. because it adds software for standardized quantitative PSMA PET\/CT analysis, but adoption is still early. The AI imaging market is growing fast, yet buyers want proof, smooth workflow integration, and clearer sales traction. FDA approval of PYLARIFY in 2021 gives it a base, but the software still needs stronger evidence to scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e1095\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003e1095 is a PSMA-targeted iodine-131 small molecule in development, so it fits the Question Marks box in Lantheus Holdings, Inc. BCG Matrix. The prostate cancer radiopharmaceutical market is expanding fast, but 1095 has no current market share or revenue base yet. It is still a development-stage option, so success will depend on clinical data, approval, and launch timing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLMI 1195\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLMI 1195 fits the \"Question Mark\" box in the BCG Matrix: it targets neuroblastoma, a rare pediatric cancer with about 600 U.S. cases a year, but it still has little commercial footprint. Pediatric oncology imaging and therapy remain high-need niches, so the asset has clear upside if Lantheus converts clinical data into adoption. For now, it is promising but still too early to drive meaningful sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh unmet need, low current revenue\u003c\/li\u003e\n\u003cli\u003eRare disease = small launch base\u003c\/li\u003e\n\u003cli\u003eUpside depends on clinical proof\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eleronlimab\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLeronlimab is an investigational monoclonal antibody partnered with CytoDyn, so Lantheus Holdings, Inc. has no recorded commercial share from the asset yet. Its late-stage path is still uncertain, and that makes it a classic BCG Question Mark: high potential, low visibility.\u003c\/p\u003e\n\u003cp\u003eWith no approved revenue stream and no disclosed 2026 market sales for Lantheus, the asset remains speculative rather than a proven cash generator.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestigational, not commercialized\u003c\/li\u003e\n\u003cli\u003ePartnered with CytoDyn\u003c\/li\u003e\n\u003cli\u003eNo market share for Lantheus\u003c\/li\u003e\n\u003cli\u003eHigh upside, high risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLantheus’ Question Marks: High Upside, Limited 2025\/2026 Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Lantheus Holdings, Inc. are FLYRCADO, PYLARIFY AI, 1095, and LMI 1195: each targets a growing niche, but 2025\/2026 revenue is still limited or not disclosed. That makes them high-upside, high-risk bets that need clinical proof, launch execution, and payer adoption before they can move out of the Question Mark box.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003e2025\/2026 cash signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFLYRCADO\u003c\/td\u003e\n\u003ctd\u003eLaunch stage\u003c\/td\u003e\n\u003ctd\u003eLow share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePYLARIFY AI\u003c\/td\u003e\n\u003ctd\u003eEarly adoption\u003c\/td\u003e\n\u003ctd\u003eNot material\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e1095\u003c\/td\u003e\n\u003ctd\u003eDevelopment\u003c\/td\u003e\n\u003ctd\u003eNo sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMI 1195\u003c\/td\u003e\n\u003ctd\u003eDevelopment\u003c\/td\u003e\n\u003ctd\u003eNo sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234666520841,"sku":"lnth-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lnth-bcg-matrix.webp?v=1785724027","url":"https:\/\/dcfanalyst.com\/products\/lnth-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}